Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. thyrotrust

ThyroTrust

A novel reliable diagnostic device to avoid unnecessary thyroid surgery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ThyroTrust project word cloud

Explore the words cloud of the ThyroTrust project. It provides you a very rough idea of what is the project "ThyroTrust" about.

reveal    sequencing    300    thyroidectomy    fnac    histology    panel    strategy    66    fine    patients    types    outcome    proposing    abolishment    kit    introduce    rearrangements    diagnosis    diagnostics    italy    26    scope    prudentially    unnecessary    5    time    frequent    diagnostic    hormone    surgery    feasibility    first    influences    performed    positive    44000    measured    social    thyrotrust    lt    risk    ce    opportunity    generation    either    genes    80    cytological    correct    route    procedure    innovation    cancer    90    prevalence    virtually    effect    malignant    gene    organization    47    quality    idea    business    fna    classified    market    lesion    negative    thyroid    15    ivd    adverse    30    validated    manufacturing    nodules    indeterminate    surgical    plan    addressable    tool    clinically    complications    malignancy    million    planning    ing    ipr    search    life    aspiration    financial    forcing    category    postoperative    estimation    cytology    replacement    price    740    variations    needle    expression    cos    surgeries    considerable    clinical    benign   

Project "ThyroTrust" data sheet

The following table provides information about the project.

Coordinator		 GENOMNIA SRL 

Organization address
address: CORSO MAGENTA 56
city: MILANO
postcode: 20123
website: www.genomnia.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Italy [IT]
 Project website http://www.genomnia.it
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2016-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENOMNIA SRL IT (MILANO) coordinator 50˙000.00

Map

 Project objective

Fine needle aspiration cytology (FNAC) is the best procedure for a timely and reliable diagnosis of either a benign or malignant thyroid lesion. However, the management of patients with indeterminate cytology (10-26%) is a frequent clinical and social problem, as this cytological category is associated with a 15 to 30% prevalence of malignancy, forcing most of these patients to diagnostic surgery. However, for the 80% of these patients the surgery is unnecessary as the postoperative histology reveal a benign lesion. The negative social and financial consequences of this approach are relevant in Europe (44000/year thyroidectomy only in Italy) as well as the adverse influences on the quality of life of the patients due to surgical complications and hormone replacement. We will introduce in the market the first clinically validated CE-IVD targeted Next Generation Sequencing diagnostic kit ThyroTrust for the correct diagnosis of thyroid nodules with indeterminate cytology. Our kit is the first to include a considerable number of variations in 47 genes, 66 types of rearrangements and 8 gene expression level measured at the same time and associated with malignant outcome. This will avoid diagnostic surgery if a risk of malignancy <5%. In the scope of the feasibility study we will assess: - Technology innovation opportunity and business idea - Development planning and partner search - IPR, quality, organization and manufacturing route - GO-TO-MARKET strategy and business plan 740,000 FNA are performed in Europe, so the addressable market, with an end-user price/kit of 300€, is over €50 Million/year. Prudentially, market estimation considers only FNA results classified as “indeterminate cytology”. The same approach could be evaluated and adopted for other cancer diagnostics, proposing a similar gene panel kit on the market. The positive effect resulting from such diagnostic tool can virtually lead to the abolishment of 90% of unnecessary surgeries and related cos

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THYROTRUST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THYROTRUST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More